Delivering Hope and Wellness
Hopewell is a privately held biotechnology company based in Woburn, Massachusetts. It was founded by Dr. Qiaobing Xu, Professor of Biomedical Engineering at Tufts University and a world-renowned leader in the application of material science engineering to biomedicine, with a focus on advancing the field of genomic medicine with leading-edge lipid nanoparticle (LNP) delivery technology. The company established operations with a seed financing round in January 2022.
Leveraging an extensive intellectual property portfolio licensed from Tufts and augmented at Hopewell, the company specializes in synthesizing and developing targeted, efficient, and safe LNPs supporting diverse cargoes to address unmet medical needs through its differentiated ATLAS platform.
Hopewell’s LNP platform serves as an engine for both internal pipeline programs and external collaborations. With a fully operational lab and an experienced team, Hopewell has established broad R&D capabilities spanning lipid synthesis, mRNA cargo development, and LNP development.
Deep Expertise in Novel LNP Delivery Systems and Building Successful Biopharma Companies
Board of Directors
Chief Executive Officer
Scientific Founder and
Chief Technology Officer
Tom Hennessey III
Mass Ave Capital
Harvard Management Company